A Phase 1 interventional study of MS-553 in Diabetic Macular Edema, Macular Edema and Type 2 Diabetes With Diabetic Macular Edema, sponsored by Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-29.
Sponsored by Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Macular Edema with a site in China — 18 open to participants now, 22 under way, 4 of them phase 3. Macular Edema · China.
Among the 72 studies in Macular Edema with a site in China, this one is the 53rd largest by planned enrollment of the 65 interventional ones that give a count, is one of 5 that started in 2020, is one of 9 in phase 1, reaches primary completion later than 13 of the 21 other live ones, and was the 25th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →18 of the 72 studies in Macular Edema with a site in China are open now. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18–80
Boehringer Ingelheim · Sites in China, United States, Czechia and 6 more countries
Ages 18+
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in China, United States, Australia
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 12 · Phase 3 26 · Phase 4 9
First in 2003; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 140 across the 65 interventional studies, 110 across the 7 observational. Of the 38 that completed or were terminated, 13 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 72 have an industry lead sponsor. The 10 most frequent:
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. has 1 study filed under Macular Edema — fewer than ten, so there is no comparison to draw.
5 of the studies in Macular Edema with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07515079Phase 3Bio-Thera SolutionsEfficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema | 2027-04-30 |
| NCT07019896Peking Union Medical College HospitalMinimal Vitrectomy Surgery for Epiretinal Membrane | 2026-11-30 |
| NCT06548568AbbVieA Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China | 2027-04 |
| NCT07133438First Affiliated Hospital of Chongqing Medical UniversityMecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment | 2027-05-31 |
| NCT07362927Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSafety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 72 studies in Macular Edema with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
low dose of MS-553 taken orally
Drug: MS-553
mid dose of MS-553 taken orally
Drug: MS-553
high dose of MS-553 taken orally
Drug: MS-553
MS-553
Treatment-emergent adverse events
Time frame: Baseline to Day 56
Mean change in the central retina subfield thickness (CRT)
Time frame: Baseline to Day 56
Mean change in the retinal volume
Time frame: Baseline to Day 56
Proportion of patients with >20% reduction in CRT
Time frame: Baseline to Day 56
Proportion of patients with resolution of central involved macular edema
Time frame: Baseline to Day 56
Average mean change in best corrected visual acuity
Time frame: Baseline to Day 56
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2020 (actual). Primary completion is estimated for Oct 2026, 76 months after the start.
Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 76 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PKC-beta Inhibitor MS-553
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.